Toronto, ON – April 23, 2025 – Iotron Medical, headquartered in Vancouver and Saskatoon, joined the Canadian Nuclear Isotope Council (CNIC) and its growing network of Canadian isotope innovators, strengthening the CNIC’s network in Western Canada.
Iotron Medical was founded in 1989 as a spin-out from Iotron Industries, a provider of electron beam-based material treatments for medical and industrial products. They have been leading commercialization efforts for electron beam-based radioisotope production since 2011, with their production currently focusing on copper-67 (Cu-67).
Cu-67 is a promising and versatile therapeutic radioisotope, with its beta emission energy, 61.8-hour half-life, imageable gamma energies, and centralized production all demonstrating its broad potential. Cu-67 labeled therapeutic radiopharmaceuticals may also be paired with Cu-64 or Cu-61 labeled imaging radiopharmaceuticals to produce a “perfect theranostic pair.”
“In joining the CNIC, Iotron Medical joins growing group of partners from coast to coast that are committed to maintaining a strong, thriving isotope ecosystem here in Canada, while connecting patients with the best possible diagnostics and treatments,” said James Scongack, Chair of the CNIC. “The global isotope market is seeing significant growth, with the market expected reach US$33 billion within five years, and Canadian companies like Iotron Medical will help ensure that Canada remains at the forefront of this growth. Meanwhile, as we progress towards our goal of establishing Canada as the global leader in the fight against cancer, we recognize the important role that novel isotope producers like Iotron will play in meeting that goal.”
“Iotron Medical is honored to join the Canadian Nuclear Isotope Council and we look forward to supporting and participating in its activities,” said Patrick Donahue, President and CEO of Iotron Medical. “We produce the therapeutic isotope Cu-67 in Saskatoon and are distributing it to research institutions and radiopharmaceutical companies throughout North America and Europe. We are also expanding our isotope portfolio using our photonuclear technology.”
To learn more about Iotron Medical, visit their website here: https://iotronmedical.com/
About the Canadian Nuclear Isotope Council
The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization. The CNIC supports over 100 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada’s position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come.
To learn more about the CNIC, visit www.CanadianIsotopes.ca and follow us on Facebook, Twitter, and LinkedIn, or please contact:
Melody Greaves
Executive Director and Vice President, Government Relations
Canadian Nuclear Isotope Council
melody.greaves@canadianisotopes.ca